Search results for "Research"

showing 10 items of 25967 documents

miR‐200c and phospho‐AKT as prognostic factors and mediators of osteosarcoma progression and lung metastasis

2016

Lung metastasis is the major cause of death in osteosarcoma patients. However, molecular mechanisms underlying this metastasis remain poorly understood. To identify key molecules related with pulmonary metastasis of pediatric osteosarcomas, we analyzed high-throughput miRNA expression in a cohort of 11 primary tumors and 15 lung metastases. Results were further validated with an independent cohort of 10 primary tumors and 6 metastases. In parallel, we performed immunohistochemical analysis of activated signaling pathways in 36 primary osteosarcomas. Only phospho-AKT associated with lower overall survival in primary tumors, supporting its role in osteosarcoma progression. CTNNB1 expression a…

0301 basic medicineOncologyMaleCancer ResearchmiR‐200cLung NeoplasmsCDH1MetastasisCohort Studies0302 clinical medicineCell MovementPhospho‐AKTPhosphorylationChildOsteosarcomabiologyGeneral MedicineArticlesCadherinsPrognosisPrimary tumorGene Expression Regulation Neoplasticmedicine.anatomical_structureLung metastasisOncology030220 oncology & carcinogenesisDisease ProgressionMolecular MedicineOsteosarcomaFemaleSignal Transductionmedicine.medical_specialtyAdolescentMesenchymal to epithelial transitionArticle03 medical and health sciencesYoung AdultAntigens CDInternal medicineCell Line TumormicroRNAGeneticsmedicineBiomarkers TumorHumansEpithelial–mesenchymal transitionCell ProliferationLungGene Expression ProfilingReproducibility of ResultsEpithelial CellsPediatric osteosarcomamedicine.diseaseSurvival AnalysisEnzyme ActivationMicroRNAs030104 developmental biologyTumor progressionbiology.proteinProto-Oncogene Proteins c-aktMolecular Oncology
researchProduct

Molecular profile in Paraguayan colorectal cancer patients, towards to a precision medicine strategy

2019

[EN] Somatic mutation analysis and evaluation of microsatellite instability (MSI) have become mandatory for selecting personalized therapy strategies for advanced colorectal cancer and are not available as routine methods in Paraguay. The aims of this study were to analyze the molecular profile as well as the microsatellite status in a series of advanced colorectal patients from two public hospitals from Paraguay, to introduce these methodologies in the routine practice to guide the therapeutic decisions. Thirty-six patients diagnosed with advanced colorectal cancer from two referent public hospitals from Paraguay were recruited from May 2017 to February 2018. Sequenom Mass spectrometry, On…

0301 basic medicineOncologyMaleCancer Researchmutational profileColorectal cancerDNA Mutational AnalysisKaplan-Meier Estimate0302 clinical medicineOriginal ResearchCancer BiologyPrecision medicineHigh-Throughput Nucleotide SequencingMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisImmunohistochemistryOncology030220 oncology & carcinogenesisFemaleMicrosatellite InstabilityDisease SusceptibilityColorectal NeoplasmsAdultmedicine.medical_specialtyprecision medicinecolorectal cancerlcsh:RC254-28203 medical and health sciencesYoung AdultInternal medicinemedicineBiomarkers TumorHumansRadiology Nuclear Medicine and imagingAgedNeoplasm Stagingbusiness.industryMicrosatellite instabilityOncocartaPrecision medicinemedicine.diseaseColorectal cancerMutational profile030104 developmental biologyMutationMicrosatellite instabilityMolecular ProfileNeoplasm GradingbusinessLENGUAJES Y SISTEMAS INFORMATICOSMicrosatellite Repeats
researchProduct

Distinct Activities of Glycolytic Enzymes Identify Chronic Lymphocytic Leukemia Patients with a more Aggressive Course and Resistance to Chemo-Immuno…

2018

A higher capacity to grow under hypoxic conditions can lead to a more aggressive behavior of tumor cells. Determining tumor activity under hypoxia may identify chronic lymphocytic leukemia (CLL) with aggressive clinical course and predict response to chemo-immunotherapy (CIT). A metabolic score was generated by determining pyruvate kinase and lactate dehydrogenase, key enzymes of glycolysis, ex vivo in primary CLL samples under normoxic and hypoxic conditions. This score was further correlated with clinical endpoints and response to CIT in 96 CLL patients. 45 patients were classified as metabolic high risk (HR), 51 as low risk (LR). Treatment-free survival (TFS) was significantly shorter in…

0301 basic medicineOncologyMaleChronic lymphocytic leukemiaHigh-risklcsh:Medicinechemistry.chemical_compoundRisk FactorsClinical endpointGlycolysisAged 80 and overlcsh:R5-920Hazard ratioGeneral MedicineMiddle AgedPrognosisFemaleImmunotherapymedicine.symptomIGHV@lcsh:Medicine (General)GlycolysisResearch PaperAdultmedicine.medical_specialtyLDHGeneral Biochemistry Genetics and Molecular BiologyDisease-Free Survival03 medical and health sciencesLactate dehydrogenaseInternal medicinemedicineBiomarkers TumorHumansPK M2AgedProportional Hazards Modelsbusiness.industrylcsh:RHypoxia (medical)medicine.diseaseLeukemia Lymphocytic Chronic B-Cell030104 developmental biologyMetabolismchemistryMutationTumor HypoxiabusinessEx vivoCLLEBioMedicine
researchProduct

Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia

2016

This test decreased time to treatment initiation by 66%–84%.

0301 basic medicineOncologyMaleEpidemiologylcsh:Medicine0302 clinical medicine1108 Medical MicrobiologyTuberculosis Multidrug-Resistant030212 general & internal medicinebacteriaDecreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test Latviabiologytime to treatment initiationDrug Resistance MicrobialMiddle Agedmultidrug-resistant tuberculosisRifampin resistanceInfectious Diseases1117 Public Health And Health ServicesTuberculosis Multidrug-Resistant/diagnosisFemaleRifampinLife Sciences & BiomedicineMicrobiology (medical)Adultmedicine.medical_specialtyTuberculosisAdolescentpulmonary030106 microbiologyXpert MTB/RIFImmunologyTime to treatmentMicrobiologylcsh:Infectious and parasitic diseasesTime-to-TreatmentMycobacterium tuberculosismolecular diagnostics03 medical and health sciencesYoung AdultAntibiotic resistancemultidrug resistanceInternal medicinemedicineHumanslcsh:RC109-216Multivariable modelantimicrobial resistanceTuberculin testAntibiotics AntitubercularScience & Technologybusiness.industryTuberculin TestResearchlcsh:RMycobacterium tuberculosis/drug effects1103 Clinical SciencesMycobacterium tuberculosisbiology.organism_classificationmedicine.diseaseAntibiotics Antitubercular/pharmacologyLatviatuberculosis and other mycobacteriaMultiple drug resistanceMODELTuberculin Test/methodsbusinessRifampin/pharmacologyMDR TB
researchProduct

Impact of Donor Activating KIR Genes on HSCT Outcome in C1-Ligand Negative Myeloid Disease Patients Transplanted with Unrelated Donors-A Retrospectiv…

2017

Natural Killer cells (NK) are lymphocytes with the potential to recognize and lyse cells which escaped T-cell mediated lysis due to their aberrant HLA expression profiles. Killer cell immunoglobulin-like receptors (KIR) influence NK-cell activity by mediation of activating or inhibitory signals upon interaction with HLA-C (C1, C2) ligands. Therefore, absence of ligands for donor inhibitory KIRs following hematopoietic stem cell transplantation (HSCT) may have an influence on its outcome. Previous studies showed that C1 negative patients have a decreased HSCT outcome. Our study, based on a cohort of 200 C1-negative patients, confirmed these findings for the endpoints: overall survival (OS: H…

0301 basic medicineOncologyMaleMyeloidCell Transplantationmedicine.medical_treatmentlcsh:MedicineHematopoietic stem cell transplantationNK cellsLigandsCohort StudiesWhite Blood Cells0302 clinical medicineMathematical and Statistical TechniquesReceptors KIRCell SignalingComplement C1Animal CellsMedicine and Health SciencesBlood and Lymphatic System ProceduresMembrane Receptor SignalingReceptorlcsh:ScienceBone Marrow TransplantationMultidisciplinaryT CellsIncidence (epidemiology)Hematopoietic Stem Cell TransplantationMiddle AgedImmune Receptor Signaling3. Good healthKiller Cells Naturalmedicine.anatomical_structureTreatment OutcomeHematologic NeoplasmsCohortPhysical SciencesFemaleCellular TypesUnrelated DonorsStatistics (Mathematics)Research ArticleSignal TransductionAdultmedicine.medical_specialtyAdolescentImmune CellsImmunologySurgical and Invasive Medical ProceduresResearch and Analysis Methods03 medical and health sciencesYoung AdultInternal medicinemedicineConfidence IntervalsHumansClinical significanceddc:610Statistical MethodsAgedRetrospective StudiesTransplantationBlood Cellsbusiness.industrylcsh:RBiology and Life SciencesRetrospective cohort studyCell BiologyMultivariate analysis; Stem cell transplantation; T cells; Bone marrow transplantation; NK cells; Hematopoietic stem cell transplantation; Immune receptor signalingTransplantation030104 developmental biologyImmunologyMultivariate Analysislcsh:QbusinessMathematics030215 immunologyStem Cell TransplantationPLoS ONE
researchProduct

Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma

2016

// Aurelie Bertaut 1 , Caroline Truntzer 2 , Rachid Madkouri 3 , Coureche Guillaume Kaderbhai 4 , Valentin Derangere 5 , Julie Vincent 4 , Bruno Chauffert 6 , Marie Helene Aubriot-Lorton 7 , Wahlid Farah 3 , Klaus Luc Mourier 3 , Romain Boidot 5,8 and Francois Ghiringhelli 4,5,8,9 1 Biostatistics unit Georges Francois Leclerc Cancer Center, Dijon, France 2 CLIPP, Research Center, University of Burgundy, Dijon, France 3 Department of Neurosurgery, CHU, Dijon, France 4 Department of Medical Oncology, Georges Francois Leclerc Cancer Center, Dijon, France 5 Platform of Transfer in Cancer Biology Genetic and histology, Georges Francois Leclerc Cancer Center, Dijon, France 6 Department of Medical…

0301 basic medicineOncologyMaleVascular Endothelial Growth Factor Agenetic structuresNeutrophilsmedicine.medical_treatmentAngiogenesis InhibitorsBiomarkers Pharmacological[ SDV.CAN ] Life Sciences [q-bio]/CancerLeukocyte Count0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactorEndothelial Growth-Factorprognostic factorNeoadjuvant therapyRandomized Controlled Trials as TopicNeovascularization PathologicBrain NeoplasmsColony-Stimulating FactorAge FactorsChemoradiotherapyMiddle AgedPrognosisNeoadjuvant Therapy3. Good healthTreatment OutcomeOncology030220 oncology & carcinogenesisTo-Lymphocyte RatioAbsolute neutrophil countFemalemedicine.drugmedicine.medical_specialtyBevacizumabMalignant Glioma[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.BC]Life Sciences [q-bio]/Cellular BiologybevacizumabDisease-Free Survival03 medical and health sciencesInternal medicinemedicineHumansPretreatment NeutrophilKarnofsky Performance StatusSingle-Agent BevacizumabRetrospective StudiesNewly-Diagnosed GlioblastomaRecurrent Glioblastomabusiness.industry[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyGene Expression ProfilingglioblastomaCancerRetrospective cohort studyLomustinemedicine.diseasePhase-Ii Trialeye diseasesSurgeryIrinotecan030104 developmental biologyprognosistic factorBrain-Tumorssense organsClinical Research PaperNeoplasm Recurrence LocalbusinessChemoradiotherapyFollow-Up Studies
researchProduct

Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel: a retrospective study.

2017

The aim of this study was to evaluate abiraterone's efficacy in Italian patients affected with metastatic prostate cancer progressing after treatment with docetaxel. We conducted a retrospective analysis of 60 patients. Prostate-specific antigen (PSA) reduction in serum was the primary endpoint for evaluating the efficacy of abiraterone in combination with prednisone treatment, whereas reduced pain, safety, progression-free survival, response rate, and overall survival (OS) were secondary endpoints. A significant correlation was noticed between PSA response and OS. Further, the Index Bravais-Pearson (r) correlation allowed us to observe a significant negative interdependence between PSA res…

0301 basic medicineOncologyMalemedicine.medical_specialtyCancer ResearchDocetaxelprostatic neoplasm03 medical and health sciencesProstate cancer0302 clinical medicinePrednisoneInternal medicineabirateroneAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansPharmacology (medical)Neoplasm MetastasisSurvival rateAgedRetrospective StudiesPharmacologyAged 80 and overbusiness.industryandrogen antagonistRetrospective cohort studyMiddle AgedProstate-Specific Antigenmedicine.diseasedrug therapyProstate-specific antigenProstatic Neoplasms Castration-Resistant030104 developmental biologyDocetaxelTolerabilitymetastatic castration-resistant prostate cancerOncology030220 oncology & carcinogenesisPrednisoneAndrostenesKallikreinsTaxoidsbusinessmedicine.drugAnti-cancer drugs
researchProduct

Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial

2020

PD1 expression in CD4+ and CD8+ T cells is increased after treatment in multiple myeloma patients with persistent disease. The GEM-Pembresid trial analyzed the efficacy and safety of pembrolizumab as consolidation in patients achieving at least very good partial response but with persistent measurable disease after first- or second-line treatment. Moreover, the characteristics of the immune system were investigated to identify potential biomarkers of response to pembrolizumab. One out of the 17 evaluable patients showed a decrease in the amount of M-protein, although a potential late effect of high-dose melphalan could not be ruled out. Fourteen adverse events were considered related to pem…

0301 basic medicineOncologyMelphalanCancer Researchmedicine.medical_specialtymedicine.medical_treatmentPembrolizumablcsh:RC254-282Article03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdverse effectMultiple myelomaPneumonitisbusiness.industryLate effectImmunotherapymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensDiscontinuation030104 developmental biologymyelomaOncology030220 oncology & carcinogenesispembrolizumabimmunotherapymedicine.symptombusinessconsolidationmedicine.drug
researchProduct

Breast cancer subtype of French women is not influenced by socioeconomic status: A population-based-study

2017

Context The molecular subtype of breast tumours plays a major role in cancer prognosis and treatment options. Triple negative tumours (TN) carry the worst prognosis and affects most frequently women of low socioeconomic status (SES). Studies have shown that non-biologic factors, such as the socioeconomic status could have an influence on tumour biology. To this date no study has been done investigating this association in French women. The objective is to study the association between the SES and the molecular tumour subtype of breast cancer patients in the French county of Cote d’Or. This study benefits from the population data from the Cote d’Or breast cancer registry known for its strict…

0301 basic medicineOncologyMultivariate analysisReceptor ErbB-2Social Scienceslcsh:MedicineBiochemistryGeographical Locations0302 clinical medicineSociologyBreast TumorsMedicine and Health SciencesEthnicitiesMedicineFrench PeopleRegistrieslcsh:ScienceLymph nodeMultidisciplinaryMiddle AgedEuropemedicine.anatomical_structureOncology030220 oncology & carcinogenesisFemaleFranceResearch ArticleAdultmedicine.medical_specialtyBreast NeoplasmsContext (language use)03 medical and health sciencesBreast cancerDiagnostic MedicineInternal medicineBreast CancerCancer Detection and DiagnosisHumansSocial StratificationSocioeconomic statusGynecologybusiness.industrylcsh:RCancers and NeoplasmsBiology and Life SciencesCancermedicine.diseaseHormonesPopulation based studyClinical trial030104 developmental biologyMetastatic TumorsSocioeconomic FactorsPeople and PlacesPopulation Groupingslcsh:QbusinessPLOS ONE
researchProduct

Melanoma Unknown Primary Brain Metastasis Treatment with ECHO-7 Oncolytic Virus Rigvir: A Case Report

2018

Melanoma is considered an aggressive malignancy with a tendency for forming metastasis in the brain. Less than 10% of all melanoma cases present with unknown primary tumor location. This diagnose is yet to be fully understood, because there are only theoretical assumptions about the nature of this disease. Melanoma brain metastases have many severe side effects and unfortunately, any disease related to the brain has limited therapeutic options due to the blood brain barrier. The course of the disease after completing a treatment course, and stopping the treatment, is complicated to predict and is difficult to obtain long-lasting remission. In this report we describe a female patient with un…

0301 basic medicineOncologyNasal cavityCancer Researchmedicine.medical_specialtyCentral nervous systemDiseaseMalignancyblood–brain barrierlcsh:RC254-282Metastasis03 medical and health sciences0302 clinical medicinemelanoma brain metastasisInternal medicinemedicineECHO-7 virusoncolytic virusbusiness.industryMelanomaintranasalmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensOncolytic virus030104 developmental biologymedicine.anatomical_structureOncologymelanoma unknown primary030220 oncology & carcinogenesisbusinessBrain metastasisFrontiers in Oncology
researchProduct